Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seladelpar - CymaBay Therapeutics

Drug Profile

Seladelpar - CymaBay Therapeutics

Alternative Names: MBX 8025; RWJ 800025

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ortho-McNeil
  • Developer CymaBay Therapeutics
  • Class Acetates; Anti-inflammatories; Antifibrotics; Antihyperlipidaemics; Hepatoprotectants
  • Mechanism of Action C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type V; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa; Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary biliary cirrhosis
  • Phase II Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis

Most Recent Events

  • 06 Nov 2019 CymaBay Therapeutics completes a phase-II trial in Primary biliary cirrhosis (Treatment-experienced) in Germany, United Kingdom, Canada, USA (PO) (NCT02955602)
  • 15 Aug 2019 Phase-II clinical trials in Primary sclerosing cholangitis in USA (PO) (NCT04024813)
  • 18 Jun 2019 CymaBay Therapeutics plans a phase II trial for Primary sclerosing cholangitis in the third quarter of 2019 (NCT04024813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top